{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T15:32:41Z","timestamp":1759073561850,"version":"3.38.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[1998,7,1]],"date-time":"1998-07-01T00:00:00Z","timestamp":899251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[1998,7]]},"abstract":"<jats:p> The existence of discontinuation syndromes following treatment with neuroleptic (antipsychotic) drugs was first outlined in the mid-1960s but the effects of such syndromes have been neglected since then. We have pursued evidence for the existence and nature of discontinuation syndromes following neuroleptics through reports of difficulties following the use of dopamine blocking anti-emetics, the use of chlorpromazine to treat tuberculosis, the use of antidepressant-neuroleptic combinations in affective disorders, the occurrence of tardive syndromes and studies designed to establish the existence of discontinuation syndromes in schizophrenia. Combined these bodies of data point strongly to the existence of discontinuation syndromes after cessation of treatment with neuroleptics which may involve features other than motor dyskinesias. There is at present little evidence on the relative frequency of such syndromes or predisposing factors. The area needs research input to establish the nature of the syndromes that may result, their frequency, predisposing factors and best methods of treatment. <\/jats:p>","DOI":"10.1177\/026988119801200412","type":"journal-article","created":{"date-parts":[[2007,3,18]],"date-time":"2007-03-18T03:45:17Z","timestamp":1174189517000},"page":"401-406","source":"Crossref","is-referenced-by-count":48,"title":["Neuroleptic discontinuation syndromes"],"prefix":"10.1177","volume":"12","author":[{"given":"Richard","family":"Tranter","sequence":"first","affiliation":[{"name":"North Wales Department of Psychological Medicine, Hergest Unit, Bangor LL57 2PW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Healy","sequence":"additional","affiliation":[{"name":"North Wales Department of Psychological Medicine, Hergest Unit, Bangor LL57 2PW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1998,7,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00571-4"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950150021002"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950240089014"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.11.1485a"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(66)80030-5"},{"key":"atypb6","unstructured":"Battegay R. (1967) Drug dependence as a criterion for differentiation of psychotropic drugs. In Brill H, Cole J O, Deniker P, Hippius H, Bradley P B (eds), Neuropsychopharmacology Excerpta Medica, Amsterdam, pp. 244-252"},{"key":"atypb7","unstructured":"Carlsson A., Svensson A., Carlsson M.L. (1993) Future strategies in the discovery of new antipsychotic drugs. In Brunello N, Medlewicz J, Racagni G (eds), New generation of antipsychotic drugs: novel mechanisms of action . Karger, Basel, pp. 103-117"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950150024003"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.137.1.16"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199610000-00003"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(90)90097-Z"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.140.2.249"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.121.5.491"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950150005001"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.138.6.804"},{"key":"atypb16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1192\/bjp.164.2.149","volume":"164","author":"Goodwm G.M.","year":"1994","journal-title":"Br J Psychiat"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950150029004"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.123.2.221"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198112033052316"},{"volume-title":"From hypertension to psychopharmacology. A serendipitous career","year":"1998","author":"Hollister L.","key":"atypb20"},{"key":"atypb21","first-page":"562","volume":"81","author":"Hollister L.E.","year":"1960","journal-title":"Am Rev Resp Dis"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/19.2.303"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.7.2.223"},{"key":"atypb24","unstructured":"Lader M. (1983) Benzodiazepine withdrawal states. In Trimble M R (ed.), Benzodiazepines divided . John Wiley, New York, pp.17-31"},{"key":"atypb25","first-page":"410","volume":"11","author":"Melnyk WT","year":"1965","journal-title":"Can Psychiat Ass J"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950150032005"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830200094013"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245619"},{"key":"atypb29","first-page":"726","volume":"154","author":"Noll A.M.","year":"1991","journal-title":"West J Med"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950150035006"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.34.10.1042"},{"key":"atypb32","first-page":"210","volume":"86","author":"Patel M.","year":"1986","journal-title":"N Y St J Med"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/21.3.451"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1984.tb01230.x"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(65)80028-1"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810360046007"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830130055011"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)00201-Z"},{"volume-title":"Expert Committee on Dependence Producing Drugs","year":"1965","author":"World Health Organization","key":"atypb39"},{"key":"atypb40","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950150037007"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/026988119801200412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/026988119801200412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:54:33Z","timestamp":1740988473000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/026988119801200412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,7]]}},"alternative-id":["10.1177\/026988119801200412"],"URL":"https:\/\/doi.org\/10.1177\/026988119801200412","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"type":"print","value":"0269-8811"},{"type":"electronic","value":"1461-7285"}],"subject":[],"published":{"date-parts":[[1998,7]]}}}